BioSight
Companies
Atea Pharmaceuticals, Inc. logo

AVIR

NASDAQBOSTON, MA
Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals develops antiviral drugs targeting hepatitis C virus (HCV) and hepatitis E virus (HEV) infections. The company is in clinical development with multiple product candidates across these therapeutic areas. Atea is evaluating its business strategy and exploring strategic alternatives to advance its pipeline toward regulatory approval and potential commercialization.

Price history not yet available for AVIR.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar